191 related articles for article (PubMed ID: 27602330)
1. The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.
Ricco A; Manahan G; Lanciano R; Hanlon A; Yang J; Arrigo S; Lamond J; Feng J; Mooreville M; Garber B; Brady L
Front Oncol; 2016; 6():184. PubMed ID: 27602330
[TBL] [Abstract][Full Text] [Related]
2. SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.
Bernetich M; Oliai C; Lanciano R; Hanlon A; Lamond J; Arrigo S; Yang J; Good M; Feng J; Brown R; Garber B; Mooreville M; Brady LW
Front Oncol; 2014; 4():312. PubMed ID: 25426447
[TBL] [Abstract][Full Text] [Related]
3. Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer.
Oliai C; Bernetich M; Brady L; Yang J; Hanlon A; Lamond J; Arrigo S; Good M; Mooreville M; Garber B; Lanciano R
J Radiat Oncol; 2016; 5():187-195. PubMed ID: 27335630
[TBL] [Abstract][Full Text] [Related]
4. Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up.
Ricco A; Barbera G; Lanciano R; Feng J; Hanlon A; Lozano A; Good M; Arrigo S; Lamond J; Yang J
Front Oncol; 2020; 10():1505. PubMed ID: 33102201
[No Abstract] [Full Text] [Related]
5. [Stereotactic body radiation therapy versus conventional intensity-modulated radiation therapy for the treatment of prostate cancer].
Gao QN
Zhonghua Nan Ke Xue; 2019 May; 25(5):424-429. PubMed ID: 32216228
[TBL] [Abstract][Full Text] [Related]
6. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.
Carrasquilla M; Sholklapper T; Pepin AN; Hodgins N; Lei S; Rashid A; Danner M; Zwart A; Bolanos G; Ayoob M; Yung T; Aghdam N; Collins B; Suy S; Kumar D; Hankins R; Kowalczyk K; Dawson N; Collins S
Front Oncol; 2023; 13():1240939. PubMed ID: 38074646
[TBL] [Abstract][Full Text] [Related]
7. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer.
Ozyigit G; Onal C; Beduk Esen CS; Tilki B; Hurmuz P
Urol Oncol; 2023 May; 41(5):252.e1-252.e8. PubMed ID: 36631368
[TBL] [Abstract][Full Text] [Related]
9. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
Paydar I; Pepin A; Cyr RA; King J; Yung TM; Bullock EG; Lei S; Satinsky A; Harter KW; Suy S; Dritschilo A; Lynch JH; Kole TP; Collins SP
Front Oncol; 2017; 7():5. PubMed ID: 28224113
[TBL] [Abstract][Full Text] [Related]
10. Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database.
Ricco A; Hanlon A; Lanciano R
Front Oncol; 2017; 7():185. PubMed ID: 28913176
[TBL] [Abstract][Full Text] [Related]
11. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
12. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
[TBL] [Abstract][Full Text] [Related]
13. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
15. Transitioning from conformal radiotherapy to intensity-modulated radiotherapy after radical prostatectomy: Clinical benefit, oncologic outcomes and incidence of gastrointestinal and urinary toxicities.
Flores-Balcázar CH; Urías-Arce DM; Bourlon MT; Gabilondo-Navarro F; Pérez-Álvarez SI; Ramos-Prudencio R; Rodríguez-Covarrubias F
Rep Pract Oncol Radiother; 2020; 25(4):568-573. PubMed ID: 32494230
[TBL] [Abstract][Full Text] [Related]
16. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
[TBL] [Abstract][Full Text] [Related]
18. Impact of race on biochemical disease recurrence after prostate brachytherapy.
Yamoah K; Stone N; Stock R
Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058
[TBL] [Abstract][Full Text] [Related]
19. The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy.
Waters MR; Andruska N; Fischer-Valuck BW; Agabalogun T; Brenneman RJ; Gay H; Michalski JM; Baumann B
Cureus; 2023 Jan; 15(1):e34351. PubMed ID: 36874706
[TBL] [Abstract][Full Text] [Related]
20. Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Agrawal R; Dey A; Datta S; Nassar A; Grubb W; Traughber B; Biswas T; Ove R; Podder T
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
